July 14, 2025

Table 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 1b/2 trial examines effects of TP-0903 and decitabine on acute myeloid leukemia in patients over 60, suggesting potential therapeutic benefits.

MAIN FINDING: TP-0903 combined with decitabine shows promise for treating acute myeloid leukemia in older patients.
KEY EVIDENCE: Initial results highlight efficacy in patients with mutant tp53 or complex karyotype.
APPROACH: The study features a phase 1b/2 clinical trial design focused on patients aged 60 and above.
SIGNIFICANCE: Results may shape future treatments for acute myeloid leukemia in the elderly population.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1b/2 trial examines effects of TP-0903 and decitabine on acute myeloid leukemia in patients over 60, suggesting potential therapeutic benefits.